Enabling a new frontier in T-cell immunotherapy for currently incurable diseases by providing game-changing treatment solutions and improving outcomes for cancer patients with the highest unmet medical needs.

Our aim is to become a major player in the field of cancer cell therapy by being the leading allogenic cell therapy platform combining bispecific antibodies with allogenic cell therapy.

We are creating new opportunities for patients with blood and solid tumours who have no other treatment options, as well as for companies with bispecific antibodies to expand their market.